Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Long-Term Extension of Lu AA21004 in Major Depressive Disorder
jRCT2080221491Phase 3
- Sponsor
- Takeda
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Takeda. Primary endpoint: Long-term safety of vortioxetine.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221491.